

『結節性硬化症に伴うてんかんの治療ガイドライン 2025』正誤表

このたびは上記書籍をご購入いただきまして誠にありがとうございます。

本書に以下の誤りがございました。訂正させていただきますとともに、謹んでお詫び申し上げます。

2026年1月20日現在

診断と治療社 編集部

ページ	箇所	誤	正
p 8	文献	<p>4) Curatolo P, Franz DN, Lawson JA, et al. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex : post-hoc analysis of the phase 3 EXIST-3 trial. Lancet Child Adolesc Health. 2018 ; 2 : 495-504.</p> <p>5) French JA, Lawson JA, Yapici Z, Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3) : a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016 ; 388 : 2153-63.</p>	<p>左記の文献 4, 5 を削除し文献番号を繰り上げ</p> <p>4) Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013 ; 74 : 679-87.</p> <p>5) Krueger DA, Wilfong AA, Mays M, et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology 2016 ; 87 : 2408-15.</p> <p>6) Samuelli S, Abraham K, Dressler A, et al. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study. Orphanet J Rare Dis 2016 ; 11 : 145.</p> <p>7) Overwater IE, Rietman AB, Bindels-de Heus K, et al. Sirolimus for epilepsy in children with tuberous sclerosis complex : A randomized controlled trial. Neurology. 2016 ; 87 : 1011-8.</p> <p>8) Zhang MN, Zou LP, Wang YY, et al. Calcification in cerebral parenchyma affects pharmaco-resistant epilepsy in tuberous sclerosis. Seizure 2018 ; 60 : 86-90.</p>
p 40	文献	<p>8) Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010 ; 51 : 1236-41.</p>	<p>左記の文献 8 を削除し文献番号を繰り上げ</p> <p>8) Wu JY, Peters JM, Goyal M, et al. Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants. Pediatr Neurol 2016 ; 54 : 29-34.</p> <p>9) Krsek P, Jahodova A, Kyncl M, et al. Predictors of seizure-free outcome after epilepsy surgery for pediatric tuberous sclerosis complex. Epilepsia 2013 ; 54 : 1913-21.</p> <p>10) Zhang K, Hu WH, Zhang C, Meng FG, Chen N, Zhang JG. Predictors of seizure freedom after surgical management of tuberous sclerosis complex : A systematic review and meta-analysis. Epilepsy Res 2013 ; 105 : 377-83.</p>

			<p>11) van Eeghen AM, Chu-Shore CJ, Pulsifer MB, Camposano SE, Thiele EA. Cognitive and adaptive development of patients with tuberous sclerosis complex : a retrospective, longitudinal investigation. <i>Epilepsy Behav</i> 2012 ; 23 : 10-15.</p> <p>12) Numis AL, Major P, Montenegro MA, Muzykewicz DA, Pulsifer MB, Thiele EA. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. <i>Neurology</i> 2011 ; 76 : 981-7.</p> <p>13) Staley BA, Montenegro MA, Major P, et al. Self-injurious behavior and tuberous sclerosis complex : frequency and possible associations in a population of 257 patients. <i>Epilepsy Behav</i> 2008 ; 13 : 650-3.</p>
p 50	文献	<p>16) Vignoli A, La Briola F, Turner K, et al. Epilepsy in adult patients with tuberous sclerosis complex. <i>Acta Neurol Scand</i> 2021 ; 144 : 29-40.</p>	<p>左記文献 16 を削除し文献番号を繰り上げ</p> <p>16) Jeong A, Nakagawa JA, Wong M. Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex. <i>J Child Neurol</i> 2017 ; 32 : 1092-8</p> <p>17) Drug resistant epilepsy. EPILEPSY FOUNDATION. https://www.epilepsy.com/treatment/medicines/drug-resistant-epilepsy [閲覧日 : 2024.7.1]</p> <p>18) Perucca E, Perucca P, White HS, Wirrell EC. Drug resistance in epilepsy. <i>Lancet Neurol</i> 2023 ; 22 : 723-34.</p> <p>19) Lachhwani DK, Pestana E, Gupta A, Kotagal P, Bingaman W, Wyllie E. Identification of candidates for epilepsy surgery in patients with tuberous sclerosis. <i>Neurology</i> 2005 ; 64 : 1651-4.</p> <p>20) Bollo RJ, Kalhorn SP, Carlson C, Haegeli V, Devinsky O, Weiner HL. Epilepsy surgery and tuberous sclerosis complex : special considerations. <i>Neurosurg Focus</i> 2008 ; 25 : E13.</p> <p>21) Moavero R, Cerminara C, Curatolo P. Epilepsy secondary to tuberous sclerosis : lessons learned and current challenges. <i>Childs Nerv Syst</i> 2010 ; 26 : 1495-504.</p> <p>22) Zheng H, Chengcheng W, Bin J, et al. Deep Brain Stimulation of Anterior Thalamic Nucleus for Treatment of Patient with Tuberous Sclerosis-Related Refractory Epilepsy. <i>World Neurosurg</i> 2020 ; 138 : 141-4.</p> <p>23) McDermott DS, Mirro EA, Fetrow K, et al. Brain-Responsive Neurostimulation for the treatment of adults with epilepsy in tuberous sclerosis complex : A case series. <i>Epilepsia Open</i> 2021 ; 6 : 419-24.</p> <p>24) Coppola G, Klepper J, Ammendola E, et al. The effects of the ketogenic diet in refractory partial seizures with reference to</p>

			<p>tuberous sclerosis. Eur J Paediatr Neurol 2006 ; 10 : 148-51.</p> <p>25) Kadish NE, Riedel C, Stephani U, Wiegand G. Developmental outcomes in children/adolescents and one adult with tuberous sclerosis complex (TSC) and refractory epilepsy treated with everolimus. Epilepsy Behav 2020 ; 111 : 107182.</p> <p>26) Barnett JR, Grinspoon RA, Harisinghani M, Caruso PA, Thiele EA. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex. J Clin Neurosci 2020 ; 77 : 85-8.</p>
p 65	文献	<p>14) Elliott RE, Carlson C, Kalhorn SP, et al. Refractory epilepsy in tuberous sclerosis : vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav 2009 ; 16 : 454-60.</p>	<p>左記文献 14 を削除し文献番号を繰り上げ</p> <p>14) 浜野晋一郎, 編. 新分類・新薬でわかる小児けいれん・てんかん診療—Classification and Practice. 東京: 中山書店, 2022.</p> <p>15) French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3) : a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016 ; 388 : 2153-63.</p> <p>16) Franz DN, Lawson JA, Yapici Z, et al. Everolimus for treatment-refractory seizures in TSC : Extension of a randomized controlled trial. Neurol Clin Pract 2018 ; 8 : 412-20.</p> <p>17) Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangiomyomatosis (EXIST-2) : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013 ; 381 : 817-24.</p> <p>18) Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1) : a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013 ; 381 : 125-32.</p> <p>19) Specchio N, Nabbout R, Aronica E, et al. Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy. Eur J Paediatr Neurol 2023; 47 : 25-34.</p>